ClinicalTrials.gg
Drug

Deucravacitinib clinical trials

Also written BMS-986165 and SOTYKTU.

studies test it
78
open now
11
in phase 3
16
first study started
2016

How each study uses deucravacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the deucravacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
9 Sept 2022 · SOTYKTU · NDA 214958 (FDA, Drugs@FDA)
European Union
24 Mar 2023 · Sotyktu · EMEA/H/C/005755 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Deucravacitinib
44
BMS-986165 Tablet
2

Brand

SOTYKTU
8

Development codes

BMS-986165
47

Studies by the year they started

78 studies that test it; most in 2019 (18)

Studies that test deucravacitinib, by start year
YearStudies
20161
20175
20189
201918
20204
20217
20223
20239
202410
20257
20265

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
28
Phase 2
20
Phase 3
16
Phase 4
12
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 60 · Other 18

Bristol-Myers Squibb (59) · Centre Hospitalier Universitaire de Nice (2) · Mayo Clinic (2) · University of California, San Francisco (2) · Icahn School of Medicine at Mount Sinai (2) · AbbVie (1) · University of Alabama at Birmingham (1) · Psoriasis Treatment Center of Central New Jersey (1)

Often tested with

Tested in the same studies.

Risankizumab (2) · Ustekinumab (2) · Fluvoxamine (1) · BMS-986165-01 (1) · Pyrimethamine (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Deucravacitinib is the comparator. A study of two new drugs counts under both.

  • 1TQH3906 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · next primary completion Sep 2027
Reaching primary completion within a year · 2, 1 in phase 3

Studies that test deucravacitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses deucravacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 78

See all 78 studies that test deucravacitinib →

Given beside what is tested · 5 — deucravacitinib is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with deucravacitinib

Codes

What other systems call deucravacitinib · ClinicalTrials.gg INT000999

  • MeSH (NLM) C000628674deucravacitinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) N0A21N6RAUDEUCRAVACITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2612087One source FDA
  • Wikidata Q113940477deucravacitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174730DeucravacitinibOne source FDA
  • DrugBank DB16650One source Wikidata

Also registered as deucravacitinib hydrochloride (UNII 95C5558CF4).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.